La calcificazione vascolare nel paziente con insuf... - ResearchGate

M. Cozzolino et al.: La calcificazione vascolare nel paziente con insufficienza renale cronica 51
5. Moranne O, Froissart M, Rossert J, et al. Timing of
onset of CKD-related metabolic complications. J Am
Soc Nephrol 2009; 20: 164-71.
6. Ix JH, Shlipak MG, Wassel CL, Whooley MA. Fibroblast
growth factor-23 and early decrements in kidney
function: The Heart And Soul Study. Nephrol
Dial Transplant 2010; 25: 993-7.
7. Kanbay M, Goldsmith D, Akcay A, Covic A. Phosphate:
the silent stealthy cardiorenal culprit in all
stages of chronic kidney disease. Blood Purif 2009;
27: 220-30.
8. Mirza MA, Larsson A, Lind L, et al. Circulating fibroblast
growth factor-23 is associated with vascular
dysfunction in the community. Atherosclerosis
2009; 205: 385-90.
9. Onufrak SJ, Bellasi A, Shaw LJ, et al. Phosphorus
levels are associated with subclinical atherosclerosis
in the general population. Atherosclerosis 2008;
199: 424-31.
10. Foley RN, CollinsAJ, Herzog CA, et al. Serum phosphorus
levels associate with coronary atherosclerosis
in young adults. J Am Soc Nephrol 2009; 20: 397-404.
11. Detrano R, Guerci AD, Carr JJ, et al. Coronary calcium
as a predictor of coronary events in four racial
or ethnic groups. N Engl J Med 2008; 358: 1336-45.
12. Watanabe E, Lemos MM, Manfredi SR, Draibe SA,
Canziani ME. Impact of cardiovascular calcification
in nondialyzed patients after 24 months of followup.
Clin J Am Soc Nephrol 2010; 5: 189-94.
13. Block GA, Raggi P, Bellasi A, Kooienga L, Spiegel
DM. Mortality effect of coronary calcification and
phosphate binder choice in incident hemodialysis patients.
Kidney Int 2007; 71: 438-41.
14. Isakova T, Gutiérrez OM, Chang Y, et al. Phosphorus
binders and survival on hemodialysis. J Am Soc Nephrol
2009; 20: 388-96.
15. Silver J, Kilav R, Naveh-Many T, et al. Mechanisms
of secondary hyperparathyroidism. Am J Physiol Renal
Physiol 2002; 283: 367-76.
16. Cozzolino M, Dusso AS, Liapis H, et al. The effects of
sevelamer hydrochloride and calcium carbonate on
kidney calcification in uremic rats. J Am Soc Nephrol
2002; 13: 2299-308.
17. Adeney K, Siscovick D, Ix J, et al. Association of serum
phosphate with vascular and valvular calcification in
moderate CKD. J Am Soc Nephrol 2009; 20: 381-7.
18. Mathew S, Lund R, Chaudhary L, Geurs T, Hruska
K. Vitamin D receptor activators can protect against
vascular calcification. J Am Soc Nephrol 2009; 19:
1509-19.
19. Cozzolino M, Brancaccio D, Gallieni M, Slatopolsky
E. Pathogenesis of vascular calcification in chronic
kidney disease. Kidney Int 2005; 68: 429-36.
20. Cozzolino M, Staniforth ME, Liapis H, et al. Sevelamer
hydrochloride attenuates kidney and cardiovascular
calcifications in long-term experimental uremia.
Kidney Int 2003; 64: 1653-61.
21. Dhingra, R, Sullivan LM, Fox CS, et al. Relations of
serum phosphorus and calcium levels to the incidence
of cardiovascular disease in the community.
Arch Intern Med 2007; 167: 879-85.
22. Tonelli M, Sacks F, Pfeffer M, Gao Z, Curhan G. Relation
between serum phosphate level and cardiovascular
event rate in people with coronary disease.
Circulation 2005; 112: 2627-33.
23. Kestenbaum B, Sampson JN, Rudser KD, et al. Serum
phosphate levels and mortality risk among people
with chronic kidney disease. J Am Soc Nephrol
2005; 16: 520-8.
24. Voormolen N, Noordzij M, Grootendorst DC, et al.
PREPARE study group. High plasma phosphate as a
risk factor for decline in renal function and mortality
in pre-dialysis patients. Nephrol Dial Transplant
2007; 22: 2909-16. Epub 2007.
25. Young EW, Albert JM, Satayathum S, et al. Predictors
and consequences of altered mineral metabolism:
the Dialysis Outcomes and Practice Patterns
Study. Kidney Int 2005; 67: 1179-87.
26. Liu S, Guo R, Simpson LG, et al. Regulation of
FGF23 expression but not degradation by Phex. J
Biol Chem 2003; 278: 37419-26.
27. Riminucci M, Collins MT, Fedarko NS, et al. FGF-23
infibrous dysplasia of bone and its relationship to renal
phosphate wasting. J Clin Invest 2003; 112: 683:92.
28. Fukumoto S. Physiological regulation and disordersof
phosphate metabolism: pivotal role of fibroblast
growth factor 23. Intern Med 2008; 47: 337-43.
29. Saito T, Fukumoto S. Fibroblast Growth Factor 23
(FGF23) and Disorders of Phosphate Metabolism. Int
J Pediatr Endocrinol 2009; 2009: 496514. Epub 2009.
30. Gutierrez O, Isakova T, Rhee E, et al. Fibroblast
growth-factor-23 mitigates hyperphosphatemia but
accentuates calcitriol deficiency in chronic kidneydisease.
J Am Soc Nephrol 2005; 16: 2205-15.
31. Gutierrez OM, Januzzi JL, IsakovaT, et al. Fibroblast
growth factor 23 and left ventricular hypertrophy
in chronic kidney disease. Circulation 2009; 119:
2545-52.
32. Westerberg PA, Linde T, Wikstrom B, et al. Regulation
offibroblast growth factor-23 in chronic kidney
disease. Nephrol Dial Transplant 2007; 22: 3202-7.
33. Nakanishi S, Kazama JJ, Nii-Kono T, et al. Serum fibroblast
growth factor-23 levels predict the future
refractory hyperparathyroidism in dialysis patients.
Kidney Int 2005; 67: 1171-8.
34. Fliser D, Kollerits B, Neyer U, et al. Fibroblast
growth factor 23 (FGF23) predicts progression of
chronic kidney disease: The Mild To Moderate Kidney
Disease (MMKD) Study. J Am Soc Nephrol 2007;
18: 2600-8.
35. Mirza M, Hansen T, Johansson L, et al. Relationship
between circulating FGF23 and total body atherosclerosis
in the community. Nephrol Dial Transplant
2009; 24: 3125-31.
36. Mirza M, Larsson A , Melhus H, Lind L, Larsson TE.
Serum intact FGF23 associate with left ventricular
mass, hypertrophy and geometry in an elderly population.
Atherosclerosis 2009; 207: 546-51.
37. Nasrallah M, Amal R, El-Shehaby AR, et al. Fibroblast
growth factor-23 (FGF-23) is independently
correlated to aortic calcification in haemodialysis patients.
Nephrol Dial Transplant 2010; 25: 2679-85.
38. Jean G, Bresson E, Terrat JC, et al. Peripheralvascular
calcification in long-haemodialysis patients:
associated factors and survival consequences. Nephrol
Dial Transplant 2009; 24: 948-55.
39. Manghat P, Fraser WD, Wierzbicki AS, Fogelman I,
Goldsmith DJ, Hampson G. Fibroblast growth factor-23
is associated with C-reactive protein, serum
phosphate and bone mineral density in chronic kidney
disease. Osteoporos Int 2009.
40. Nagano N, Miyata S, Abe M, et al. Effect of manipulating
serum phosphorus with phosphate binder on
circulating PTH and FGF23 in renal failure rats.
Kidney Int 2006; 69: 531-7.
41. Koiwa F, Onoda N, Kato H, et al. Prospective randomized
multicenter trial of sevelamer hydrochloride
and calcium carbonate for the treatment of hyperphosphatemia
in hemodialysispatients in Japan.
Ther Apher Dial 2005; 9: 340-6.
42. Oliveira R, Cancela A, Graciolli FG, et al. Early control
of PTH and FGF23 in normophosphatemic CKD
patients: a new target in CKD-MBD therapy? Clin J
Am Soc Nephrol 2010; 5: 286-91.